de Wasatch Advisors Esperion Therapeutics ESPR Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Vender |
-1,930,185
| Cerradas | -USD 6.1 M | – | 233 |
|
|
2026
Q2 | USD 6.1 M | Vender |
1,930,185
-13,838,712
| -88% | -USD 38.7 M | 0.04% | 167 |
|
|
2026
Q1 | USD 43.2 M | Comprar |
15,768,897
+6,323,138
| +67% | +USD 20 M | 0.29% | 85 |
|
|
2025
Q4 | USD 34.9 M | Comprar |
9,445,759
+2,383,902
| +34% | +USD 7.7 M | 0.21% | 97 |
|
|
2025
Q3 | USD 18.7 M | Vender |
7,061,857
-3,278,404
| -32% | -USD 6.34 M | 0.1% | 129 |
|
|
2025
Q2 | USD 10.2 M | Vender |
10,340,261
-590,996
| -5% | -USD 592 k | 0.05% | 157 |
|
|
2025
Q1 | USD 15.7 M | Vender |
10,931,257
-13,551,001
| -55% | -USD 25 M | 0.09% | 137 |
|
|
2024
Q4 | USD 53.9 M | Comprar |
24,482,258
+1,136,245
| +5% | +USD 2.65 M | 0.27% | 93 |
|
|
2024
Q3 | USD 38.5 M | Comprar |
23,346,013
+6,483,070
| +38% | +USD 13.1 M | 0.19% | 106 |
|
|
2024
Q2 | USD 37.4 M | Comprar |
16,862,943
+7,733,296
| +85% | +USD 18.2 M | 0.2% | 106 |
|
|
2024
Q1 | USD 24.5 M | Comprar |
9,129,647
+238,544
| +3% | +USD 580 k | 0.13% | 124 |
|
|
2023
Q4 | USD 26.6 M | Vender |
8,891,103
-2,634,997
| -23% | -USD 3.42 M | 0.15% | 115 |
|
|
2023
Q3 | USD 11.3 M | Vender |
11,526,100
-1,613,456
| -12% | -USD 2.33 M | 0.07% | 139 |
|
|
2023
Q2 | USD 18.3 M | Vender |
13,139,556
-214,630
| -2% | -USD 300 k | 0.11% | 133 |
|
|
2023
Q1 | USD 21.2 M | Comprar |
13,354,186
+6,505,808
| +95% | +USD 33.6 M | 0.13% | 131 |
|
|
2022
Q4 | USD 42.7 M | Vender |
6,848,378
-614,638
| -8% | -USD 4.4 M | 0.29% | 83 |
|
|
2022
Q3 | USD 50 M | Vender |
7,463,016
-82,992
| -1% | -USD 570 k | 0.35% | 78 |
|
|
2022
Q2 | USD 48 M | Vender |
7,546,008
-601,372
| -7% | -USD 3.41 M | 0.3% | 89 |
|
|
2022
Q1 | USD 37.8 M | Comprar |
8,147,380
+1,761,117
| +28% | +USD 7.55 M | 0.19% | 109 |
|
|
2021
Q4 | USD 31.9 M | Comprar |
6,386,263
+3,111,903
| +95% | +USD 24.9 M | 0.13% | 139 |
|
|
2021
Q3 | USD 39.5 M | Vender |
3,274,360
-492,575
| -13% | -USD 7.17 M | 0.16% | 130 |
|
|
2021
Q2 | USD 79.7 M | Vender |
3,766,935
-351,150
| -9% | -USD 8.46 M | 0.32% | 88 |
|
|
2021
Q1 | USD 116 M | Comprar |
4,118,085
+120,075
| +3% | +USD 3.54 M | 0.52% | 68 |
|
|
2020
Q4 | USD 104 M | Comprar |
3,998,010
+1,588,327
| +66% | +USD 47.6 M | 0.51% | 69 |
|
|
2020
Q3 | USD 89.6 M | Comprar |
2,409,683
+1,165,257
| +94% | +USD 46.2 M | 0.57% | 59 |
|
|
2020
Q2 | USD 63.9 M | Comprar |
1,244,426
+338,090
| +37% | +USD 14.1 M | 0.46% | 74 |
|
|
2020
Q1 | USD 28.6 M | Comprar |
906,336
+241,629
| +36% | +USD 12.8 M | 0.3% | 78 |
|
|
2019
Q4 | USD 39.6 M | Comprar |
664,707
+34,310
| +5% | +USD 1.54 M | 0.33% | 84 |
|
|
2019
Q3 | USD 23.1 M | Vender |
630,397
-7,978
| -1% | -USD 316 k | 0.22% | 97 |
|
|
2019
Q2 | USD 29.7 M | Comprar |
638,375
+586
| +0.1% | +USD 27.5 k | 0.29% | 83 |
|
|
2019
Q1 | USD 25.6 M | Comprar |
637,789
+75,165
| +13% | +USD 3.37 M | 0.28% | 80 |
|
|
2018
Q4 | USD 25.9 M | Comprar |
562,624
+5,339
| +1% | +USD 257 k | 0.35% | 74 |
|
|
2018
Q3 | USD 24.7 M | Comprar |
557,285
+16,273
| +3% | +USD 747 k | 0.28% | 78 |
|
|
2018
Q2 | USD 21.2 M | Vender |
541,012
-50,230
| -8% | -USD 2.54 M | 0.26% | 80 |
|
|
2018
Q1 | USD 42.8 M | Vender |
591,242
-102,023
| -15% | -USD 7.49 M | 0.55% | 62 |
|
|
2017
Q4 | USD 45.6 M | Vender |
693,265
-20,139
| -3% | -USD 1.08 M | 0.61% | 61 |
|
|
2017
Q3 | USD 35.8 M | Vender |
713,404
-42,311
| -6% | -USD 2.04 M | 0.49% | 69 |
|
|
2017
Q2 | USD 35 M | Vender |
755,715
-10,828
| -1% | -USD 398 k | 0.49% | 64 |
|
|
2017
Q1 | USD 27.1 M | Comprar |
766,543
+228,349
| +42% | +USD 5.23 M | 0.4% | 73 |
|
|
2016
Q4 | USD 6.74 M | Comprar |
538,194
+11,477
| +2% | +USD 137 k | 0.1% | 149 |
|
|
2016
Q3 | USD 7.3 M | Vender |
526,717
-7,057
| -1% | -USD 80 k | 0.11% | 157 |
|
|
2016
Q2 | USD 5.27 M | Vender |
533,774
-225,409
| -30% | -USD 3.74 M | 0.08% | 200 |
|
|
2016
Q1 | USD 12.5 M | Comprar |
759,183
+43,602
| +6% | +USD 701 k | 0.19% | 125 |
|
|
2015
Q4 | USD 15.9 M | Comprar |
715,581
+25,208
| +4% | +USD 636 k | 0.22% | 120 |
|
|
2015
Q3 | USD 16.3 M | Vender |
690,373
-12,960
| -2% | -USD 813 k | 0.22% | 131 |
|
|
2015
Q2 | USD 57.5 M | Vender |
703,333
-52,238
| -7% | -USD 5.11 M | 0.63% | 51 |
|
|
2015
Q1 | USD 70 M | Vender |
755,571
-247,151
| -25% | -USD 15.9 M | 0.73% | 39 |
|
|
2014
Q4 | USD 40.6 M | Comprar |
1,002,722
+418,688
| +72% | +USD 12.8 M | 0.42% | 89 |
|
|
2014
Q3 | USD 14.3 M | Vender |
584,034
-19,997
| -3% | -USD 318 k | 0.15% | 152 |
|
|
2014
Q2 | USD 9.6 M | Vender |
604,031
-2,533
| -0.4% | -USD 36.6 k | 0.09% | 208 |
|
|
2014
Q1 | USD 9.17 M | Vender |
606,564
-13,260
| -2% | -USD 206 k | 0.09% | 207 |
|
|
2013
Q4 | USD 8.52 M | Comprar |
619,824
+189,529
| +44% | +USD 2.76 M | 0.08% | 204 |
|
|
2013
Q3 | USD 8.12 M | Comprar |
430,295
+9,842
| +2% | +USD 165 k | 0.08% | 207 |
|
|
2013
Q2 | USD 5.93 M | Comprar |
+420,453
| Nuevas | +USD 5.97 M | 0.07% | 238 |
|
Posición de Wasatch Advisors en ESPR: resumen de T3 2026
Wasatch Advisors cerró por completo su posición en Esperion Therapeutics (ESPR) en T3 2026, liquidando una posición de 1,930,185 acciones por un valor estimado de USD 6.1 M.
Wasatch Advisors reportó por primera vez una posición en ESPR en T2 2013 y la mantuvo durante 53 trimestres. La posición alcanzó su máximo de USD 116 M en T1 2021. Al cierre de T3 2026, 0 fondos que sigue Wall St. Rank mantienen una posición en ESPR.
- Wasatch Advisors reportó que ya no tenía una posición en Esperion Therapeutics al cierre de T3 2026, después de venderla por completo durante el trimestre.
- Wasatch Advisors vendió 1,930,185 acciones de Esperion Therapeutics en T3 2026, por un valor estimado de USD 6.1 M.
- Wasatch Advisors reportó por primera vez una posición en Esperion Therapeutics en T2 2013 y la mantuvo durante 53 trimestres.
- La posición de Wasatch Advisors en Esperion Therapeutics alcanzó su máximo de USD 116 M en T1 2021.
- Al cierre de T3 2026, 0 fondos que sigue Wall St. Rank tenían Esperion Therapeutics en cartera.
Según el Informe 13F de Wasatch Advisors correspondiente a T3 2026, presentado el 13 oct 2026.